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Commentary 2 
Hospital formulary committees are increasingly being 
pressured from two sides. Hospital administrators, feeling 
the crunch of prospective reimbursement, are pressuring 
departments in their institutions to cut costs. Thus, the 
pressure on formulary committees is to trim, restrict and 
control whenever possible. On the other side, pharmaceu- 
tical manufacturers are spewing out an array of clinically 
attractive, but expensive new drugs. Some of the most 
prevalent and pervasive of these are antimicrobial agents, 
particularly cephalosporins. Hence, the pressure is on for- 
mulary committees to review and adopt new agents if they 
are even marginally superior to older, less costly products. 
An important marketing tool in today's health care envi- 
ronment is the buzzword "cost-effective." Attaching this 
label to any new drug adds to the pressure on formulary 
committees to add this agent to the hospital's drug list. 
Restriction policies to limit drug use aside, this simple act 
of approving a new drug for use in a hospital, particularly a 
teaching institution whose policies influence other local 
hospitals, is analogous to the Good Housekeeping Seal of 
Approval. Therefore, it is absolutely imperative that mem- 
bers of formulary committees clearly understand that 
"cost-effective" does not only mean that the drug is less 
expensive to administer. A long half-life and prolonged 
dosing intervals do not equate with cost-effectiveness. The 
drug must be clinically effective at the prescribed dosing 
regimens before the cost-effective label is relevant. 
The dilemma of cefonicid is that the drug is priced such 
that its once daily dosing regimen makes the total cost less 
than first generation cephalosporins that are traditionally 
given three to four times a day. However, the cefonicid 
clinical trials have yet to be published and therefore cannot 
be closely scrutinized. The preliminary reports appear to 
be very promising with the exception of the failures in 
staphylococcal endocarditis. A supplement to the Reviews 
of lnfectious Diseases to be published in late 1984 will 
contain the bulk of the clinical experience with cefonicid. 
Until that time and until more experience is gained to as- 
certain and document the clinical effectiveness of the drug, 
formulary committees should be cautious in adopting ce- 
fonicid. If this experience is positive, there is no question 
that the drug will be truly cost-effective. 
Steven L. Barriere, Pharm.D. 
College of Pharmacy 
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Commentary 3 
Cefonicid is another new cephalosporin in search of its 
appropriate place in our formularies. Its antimicrobial spec- 
trum is nearly equivalent to that of cefamandole, which it 
closely resembles. Its major difference is a markedly pro- 
longed half-life, which permits its promotion as a drug that 
can be given only once a day. 
In evaluating cefonicid, problems arise which are by no 
means unique for this drug, but which are difficult for the 
clinician to interpret. In vitro, its efficacy is markedly de- 
creased by testing in serum, rather than in broth, and such 
testing is also influenced by inoculum size. In vivo, its high 
degree of protein-binding may account for its strikingly 
high blood levels, but this attribute also strikingly shrinks its 
volume of distribution. Such reservations may be ignored, 
but they add up to giving us pause when we learn that 
plasma concentrations are above many reasonable MlCs 
at 12 hours, but only "detectable" (projected to 1 pg/ml) at 
24 hours, a level above the MIC for only a few organisms.' 
Even for those who support peak-trough dosing, one might 
wonder how long would serum levels fall below the MIC in 
this second 12 hours. This may, of course, account for the 
difficulty in being sure of the role of this drug in staphylo- 
coccal infections, and even of the possibility of paradoxic 
benefit in osteomyelitis, but perhaps not in soft-tissue in- 
fection. This requires further clarification. 
The prolonged half-life and once-daily dose leads to two 
kinds of savings - one of cost and one of efficiency or 
convenience - and these must be examined separately. 
In considering cost alone, the cost of cefonicid should be 
compared with its most likely competitor: cefamandole. 
Courses of 2 g every 24 hours of cefonicid are more expen- 
sive than 1 g every 6 hours of cefamandole according to 
the average wholesale price in Drug Topics Red Book.' 
Many of the series cited in Pontzer and Kaye's review 
examine courses of only 1 g every 24 hours. At this dose 
cefonicid is much less expensive. In institutions using any 
form of unit dose systems, requiring separate administra- 
tion sets or tubing for each dose, the overall saving in 
single daily doses is immediately evident. However, until 
further clinical trials assure us of the safety of single daily 
doses, the cost question alone is not likely to predominate, 
especially for institutions mixing a full daily dose in a single 
intravenous bottle. 
There may well be a number of situations, however, in 
which convenience or accessibility are also much better 
with daily regimens. Home care, particularly for long 
courses of antibiotics as in treatment of osteomyelitis, is 
certainly one such area. One should note with caution, 
however, that the other common infection requiring long 
courses of antibiotics, endocarditis, has had much more 
discouraging results in the trials cited by Pontzer and 
Kaye. The population used - Staphylococcus aureus en- 
docarditis in drug addicts - is admittedly a most stringent 
~ tandard .~  
The domiciliary situations where once daily administra- 
tion of a parenteral antibiotic of this spectrum may be most 
helpful is not in the acute-care hospital, where more con- 
servative and aggressive care is more justifiable, but in 
chronic-care facilities, nursing homes and the like. In these 
settings nursing staffing or limited intravenous access 
might make a single daily dose of antibiotic most accept- 
able, particularly since its efficacy in the commonest infec- 
tions found in such places seeins reasonably well docu- 
mented: urinary tract infections, soft-tissue infections 
(although with uncertainty about staphylococci) and per- 
haps pneumonia. Those seeking to use cefonicid in this 
setting should remain suspicious of the tendency to find 
highly-resistant gram-negative bacilli appearing in some 
such institutions, particularly in urinary tract infections, Of- 
ten in epidemic patterns. 
The difficulty we currently have in evaluating the clinical 
place of cefonicid is that we do not yet have adequate data 
available to allow an impartial judgement. Many of the 
clinical trials, as the authors point out, are "limited to open, 
non-blinded, comparative trials" with inadequate numbers 
